Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study

In a retrospective multicenter cohort study, this research observed that baricitinib was effective and well-tolerated in treating adult patients with alopecia areata, including those with severe cases, showing promise in improving outcomes over a 12-month period with manageable side effects.

In this study at Tohoku University Hospital, 41% of severe alopecia areata patients achieved significant hair regrowth with baricitinib treatment over 9 months, with predictors of better outcomes including shorter disease duration, female sex, initial mild disease, certain alopecia types, and prior IVMP therapy.

This study suggests that while adding baricitinib to formularies may increase costs for government hospitals, it could expand treatment options and potentially improve outcomes for patients with AA. Further analyses are recommended to assess its cost-effectiveness in terms of outcomes improvement.

Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

This review identified that baricitinib increases both short- and long-term hair regrowth in patients with alopecia areata compared to placebo, but found inconclusive results for serious adverse effects, while evidence for other treatments remains very uncertain.

In this study, combining baricitinib and prednisone effectively achieved complete hair regrowth in seven out of eight women with very severe alopecia areata, contrasting with less effective results from each drug used alone.

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.

This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.

This review discusses recent advances in understanding and treating alopecia areata, emphasizing the ongoing challenges and unmet needs in disease management; it reports no new clinical findings.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.

This study found that among an Asian population with alopecia areata, commonly first episodes occurred before age 40, with severe cases linked to psychological effects and treatments showing significant regrowth.